Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Declines By 5.9%

Candel Therapeutics, Inc. (NASDAQ:CADL) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a decrease of 5.9% from the September 15th total of 1,690,000 shares. Currently, 8.2% of the company’s stock are short sold. Based on an average trading volume of 285,900 shares, the short-interest ratio is currently 5.6 days.

Candel Therapeutics Stock Performance

CADL stock traded up $0.27 during midday trading on Wednesday, reaching $6.23. 352,872 shares of the company were exchanged, compared to its average volume of 1,982,879. The firm has a market capitalization of $185.23 million, a price-to-earnings ratio of -4.86 and a beta of -0.95. The business has a 50-day moving average price of $6.33 and a two-hundred day moving average price of $6.81. Candel Therapeutics has a one year low of $0.66 and a one year high of $14.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter. Equities research analysts forecast that Candel Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now directly owns 929,873 shares in the company, valued at $5,597,835.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 31,800 shares of company stock worth $193,380. Corporate insiders own 41.60% of the company’s stock.

Institutional Trading of Candel Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Candel Therapeutics during the 2nd quarter worth $31,000. Rhumbline Advisers bought a new stake in shares of Candel Therapeutics in the second quarter valued at about $143,000. Cubist Systematic Strategies LLC acquired a new position in shares of Candel Therapeutics in the second quarter valued at about $162,000. Finally, Bank of New York Mellon Corp bought a new position in Candel Therapeutics during the second quarter worth about $338,000. 13.93% of the stock is currently owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.